Showing results (91-100 of 127) with videos related to
Sort By:
Pageof 13
BMC Rheumatology|July 2, 2021
Innovative trial approaches in immune-mediated inflammatory diseases: current use and future potentialMichael J Grayling, Theophile Bigirumurame, Svetlana Cherlin, et al.Trials|April 10, 2026
Applying a hypothetical strategy to the intercurrent event of non-adherence with the parametric g-formula: a post hoc secondary analysis of the MET-PREVENT randomised controlled trialShaun Hiu, Nina Wilson, Kevin Wilson, et al.Nanomedicine : Nanotechnology, Biology, and Medicine|November 27, 2012
Sensitization of pancreatic cancer cells to radiation by cerium oxide nanoparticle-induced ROS productionMelissa S Wason, Jimmie Colon, Soumen Das, et al.Statistics in Medicine|March 18, 2021
Bayesian design and analysis of external pilot trials for complex interventionsDuncan T Wilson, James M S Wason, Julia Brown, et al.The American Statistician|January 7, 2022
A Review of Bayesian Perspectives on Sample Size Derivation for Confirmatory TrialsKevin Kunzmann, Michael J Grayling, Kim May Lee, et al.BMJ Open|June 27, 2023
Current practices in studies applying the target trial emulation framework: a protocol for a systematic reviewTheophile Bigirumurame, Shaun Kuan Wei Hiu, M Dawn Teare, et al.Statistics in Medicine|January 13, 2022
Conditional power and friends: The why and how of (un)planned, unblinded sample size recalculations in confirmatory trialsKevin Kunzmann, Michael J Grayling, Kim May Lee, et al.Journal of Dental Research|October 1, 1987
A cross-reactivity study of whole genomic DNA probes for Haemophilus actinomycetemcomitans, Bacteroides intermedius, and Bacteroides gingivalisM N Strzempko, S L Simon, C K French, et al.Oncogene|October 8, 2013
Identification of epithelial stromal interaction 1 as a novel effector downstream of Krüppel-like factor 8 in breast cancer invasion and metastasisT Li, H Lu, C Shen, et al.British Journal of Cancer|November 9, 2021
Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trialsHelen Mossop, Michael J Grayling, Ferdia A Gallagher, et al.Pageof 13